Long Term Treatment Strategies and Effectiveness of Secukinumab in Patient With JIA Subtypes of JPsA and ERA: Study From German BIKER Registry.

The goal of this study is to understand the long-term treatment strategies in children and adolescents diagnosed with ERA or JPsA who received secukinumab and achieved inactive disease and to evaluate the long-term treatment effectiveness of secukinumab in the ERA or JPsA patients in the postauthorization setting.

NCT Number	NCT07190053
Lead Sponsor	Novartis Pharmaceuticals
Conditions	Enthesitis-related Arthritis (ERA), Juvenile Psoriatic Arthritis (JPsA)
Enrollment	100 participants
Start Date	2025-12
Primary Completion	2029-09-18 (estimated)
Study Completion	2029-09-18 (estimated)
Updated on ClinicalTrials.gov	2025-09-24